RÉSUMÉ
Soluble CD163 (sCD163) is a selective marker of macrophages whose circulating levels have been found to be induced in patients with active inflammatory bowel disease (IBD). Urinary proteins are emerging as non-invasive diagnostic biomarkers, and here, sCD163 levels were measured in the urine of 18 controls and 63 patients with IBD by enzyme-linked immunosorbent assay. Urinary sCD163 levels did, however, not differentiate IBD patients from controls. Analysis of sCD163 in the serum of 51 of these patients did not show higher levels in IBD. Primary sclerosing cholangitis (PSC) is often associated with IBD, and sCD163 was higher in the urine of the 21 patients and in the serum of the 13 patients with PSC compared to patients with IBD. Of clinical relevance, urinary sCD163 levels were higher in PSC patients compared to those with other chronic liver diseases (n = 16), while serum sCD163 levels were comparable between the two groups. Serum sCD163 of IBD and PSC patients positively correlated with serum C-reactive protein. Serum creatinine and glomerular filtration rate, surrogate markers for renal function, did not significantly correlate with urinary or serum sCD163 levels in IBD or PSC patients. Moreover, urinary sCD163 was not related to fecal calprotectin levels whereas serum sCD163 of IBD patients showed a positive trend. PSC associated with IBD and PSC without underlying IBD had similar levels of urinary sCD163 while serum sCD163 tended to be higher in the latter group. In PSC patients, urinary sCD163 did not correlate with serum aminotransferase levels, gamma glutamyl transferase, alkaline phosphatase, bilirubin or the Model for End Stage Liver Disease score. Ursodeoxycholic acid was prescribed to our PSC patients and fecal levels of ursodeoxycholic acid and its conjugated forms were increased in PSC compared to IBD patients. Otherwise, fecal bile acid levels of IBD and PSC patients were almost identical, and were not correlated with urinary and serum sCD163 in PSC. In summary, our study identified urinary sCD163 as a potential biomarker for PSC.
Sujet(s)
Antigènes CD , Antigènes de différenciation des myélomonocytes , Marqueurs biologiques , Angiocholite sclérosante , Maladies inflammatoires intestinales , Récepteurs de surface cellulaire , Humains , Antigènes de différenciation des myélomonocytes/sang , Antigènes de différenciation des myélomonocytes/urine , Angiocholite sclérosante/urine , Angiocholite sclérosante/sang , Antigènes CD/sang , Antigènes CD/urine , Récepteurs de surface cellulaire/sang , Marqueurs biologiques/urine , Marqueurs biologiques/sang , Mâle , Femelle , Adulte d'âge moyen , Adulte , Maladies inflammatoires intestinales/urine , Maladies inflammatoires intestinales/sang , Sujet âgé , Protéine C-réactive/métabolisme , Protéine C-réactive/analyse , Complexe antigénique L1 leucocytaire/urine , Complexe antigénique L1 leucocytaire/sang , Complexe antigénique L1 leucocytaire/analyseRÉSUMÉ
BACKGROUND: Up to 70% of patients with ANCA-associated vasculitis (AAV) develop GN, with 26% progressing to ESKD. Diagnostic-grade and noninvasive tools to detect active renal inflammation are needed. Urinary soluble CD163 (usCD163) is a promising biomarker of active renal vasculitis, but a diagnostic-grade assay, assessment of its utility in prospective diagnosis of renal vasculitis flares, and evaluation of its utility in proteinuric states are needed. METHODS: We assessed a diagnostic-grade usCD163 assay in (1) a real-world cohort of 405 patients with AAV and 121 healthy and 488 non-AAV disease controls; (2) a prospective multicenter study of 84 patients with potential renal vasculitis flare; (3) a longitudinal multicenter cohort of 65 patients with podocytopathy; and (4) a cohort of 29 patients with AAV (with or without proteinuria) and ten controls. RESULTS: We established a diagnostic reference range, with a cutoff of 250 ng/mmol for active renal vasculitis (area under the curve [AUC], 0.978). Using this cutoff, usCD163 was elevated in renal vasculitis flare (AUC, 0.95) but remained low in flare mimics, such as nonvasculitic AKI. usCD163's specificity declined in patients with AAV who had nephrotic-range proteinuria and in those with primary podocytopathy, with 62% of patients with nephrotic syndrome displaying a "positive" usCD163. In patients with AAV and significant proteinuria, usCD163 normalization to total urine protein rather than creatinine provided the greatest clinical utility for diagnosing active renal vasculitis. CONCLUSIONS: usCD163 is elevated in renal vasculitis flare and remains low in flare mimics. Nonspecific protein leakage in nephrotic syndrome elevates usCD163 in the absence of glomerular macrophage infiltration, resulting in false-positive results; this can be corrected with urine protein normalization.
Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/urine , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Sujet âgé , Sujet âgé de 80 ans ou plus , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/diagnostic , Marqueurs biologiques , Diagnostic différentiel , Évolution de la maladie , Diagnostic précoce , Faux positifs , Femelle , Humains , Mâle , Adulte d'âge moyen , Syndrome néphrotique/urine , Études prospectives , Protéinurie/urine , Récepteurs de surface cellulaire , Valeurs de référence , Méthode en simple aveugleRÉSUMÉ
OBJECTIVES: Systemic vasculitis includes a group of disorders characterized by inflammation of the vessel wall, involving multiple systems, and can cause malignant hypertension. CD163 is a specific marker of anti-inflammatory macrophages. This study is aimed at evaluating the CD163 levels in relation to systemic vasculitis and renal involvements. METHODS: Urinary CD163 levels were retrospectively measured by enzyme-linked immunosorbent assay (ELISA) in 51 patients with systemic vasculitis, 42 essential hypertensions, and 36 healthy volunteers. The associations between urinary CD163 levels and clinical indicators were analyzed. RESULTS: Urinary CD163 levels were significantly higher in patients with systemic vasculitis [68.20 (38.25~158.78) (pg/ml)] compared to essential hypertension [43.86 (23.30-60.71) (pg/ml)] (p = 0.003) and the healthy volunteers [30.76 (9.30-54.16) (pg/ml)] (p < 0.001). Furthermore, systemic vasculitis patients with renal involvement had significantly higher urinary CD163 levels relative to patients without renal involvement [86.95 (47.61 and 192.38) pg/ml] vs. [41.99 (17.70 and 71.95) pg/ml, p = 0.005]. After control factors age, sex, and BMI, urinary CD163 levels in systemic vasculitis patients were positively correlated with serum creatinine, blood urea nitrogen, and ß-2 microglobulin (r = 0.45, 0.48, and 0.46; p = 0.001, 0.001, and 0.002, respectively). In addition, we found the level of urinary CD163 in granulomatous vasculitis (including TA, GPA, and EGPA) was significantly higher than that in necrotizing vasculitis (including PAN) [86.95 (41.99 and 184.82) pg/ml] vs. [45.73 (21.43 and 74.43) pg/ml, p = 0.016]. CONCLUSION: Urinary CD163 levels were significantly higher in patients with systemic vasculitis, especially in patients with renal involvement. Thus, urinary CD163 has the potential to be a biomarker for systemic vasculitis with renal involvement.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Maladies du rein/urine , Vascularite systémique/urine , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/urine , Études transversales , Test ELISA , Femelle , Humains , Maladies du rein/complications , Mâle , Adulte d'âge moyen , Récepteurs de surface cellulaire , Études rétrospectives , Vascularite systémique/complications , Jeune adulteRÉSUMÉ
Noninvasive biomarkers of disease activity are needed to predict disease remission status in patients with IgA nephropathy (IgAN). Soluble CD163 (sCD163), shed by monocytes and macrophages, is a potential biomarker in diseases associated with excessive macrophage activation. We investigated the association of urinary sCD163 (u-sCD163) with histopathological activity and clinical manifestations in 349 patients with biopsy-diagnosed IgAN. U-sCD163 was measured via enzyme-linked immunosorbent assay. In patients with IgAN, higher u-sCD163 levels were associated with histological lesions of greater severity, as well as more proteinuria and poorer renal function. Additionally, u-sCD163 was correlated with infiltration of tubulointerstitial CD163+ macrophages. High u-sCD163 levels (>3.57 ng/mg Cr) were associated with a 2.66-fold greater risk for IgAN remission failure in adjusted analyses. Adding u-sCD163 levels to the model containing clinical data at biopsy and MEST-C score significantly improved the risk prediction of IgAN remission status (AUC 0.788). Together, our results suggest that u-sCD163 may be a useful noninvasive biomarker to evaluate disease severity and remission status of IgAN.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Marqueurs biologiques/urine , Glomérulonéphrite à dépôts d'IgA/urine , Indice de gravité de la maladie , Adulte , Femelle , Glomérulonéphrite à dépôts d'IgA/diagnostic , Humains , Rein/anatomopathologie , Macrophages/métabolisme , Macrophages/anatomopathologie , Mâle , Adulte d'âge moyen , Valeur prédictive des tests , Pronostic , Récepteurs de surface cellulaire , Rémission spontanée , Études rétrospectives , SolubilitéRÉSUMÉ
BACKGROUND AND OBJECTIVES: ANCA-associated GN is a common cause of rapidly progressive GN, with high relapse rates. The early recognition of an ANCA-associated GN relapse is of importance to prevent loss of kidney function. Urinary soluble CD163 has been identified as a promising marker of active ANCA-associated GN. Previous studies, however, are limited by the lack of histologic data. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed urinary soluble CD163 in 95 patients with ANCA-associated vasculitis who underwent a kidney biopsy. In total, 125 kidney tissue sections (first kidney biopsy, n=67; repeated biopsy, n=58) with concurrent 24-hour urine samples were studied. Correlation analyses comparing urinary soluble CD163 levels and morphologic features of ANCA-associated GN were performed using Spearman rank correlation analysis. The diagnostic performance of biomarkers to detect relapsing ANCA-associated GN was evaluated using receiver operating characteristics curve analysis. RESULTS: High levels of urinary soluble CD163 were found in 96 (87%) of 110 biopsies with active ANCA-associated GN compared with one (7%) of 15 biopsies without active ANCA-associated GN and one (6%) of 17 healthy controls. Urinary soluble CD163 correlated with fibrinoid necrosis (Rho=0.48, P<0.001) and cellular crescents (Rho=0.70, P<0.001) on kidney biopsy. In repeated biopsies, urinary soluble CD163's sensitivity of 0.94 and specificity of 0.91 for the recognition of relapsing ANCA-associated GN appeared better than routine clinical measures. The presence of CD163+ cells in affected glomeruli confirmed urinary soluble CD163's origin. CONCLUSIONS: Urinary soluble CD163 is associated with active ANCA-associated GN and correlates with histologic features as seen in ANCA-associated GN. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_11_17_CJN07210520_final.mp3.
Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/immunologie , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Glomérulonéphrite/immunologie , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/anatomopathologie , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/urine , Marqueurs biologiques/urine , Biopsie , Femelle , Glomérulonéphrite/anatomopathologie , Glomérulonéphrite/urine , Humains , Mâle , Valeur prédictive des tests , Récepteurs de surface cellulaire , Enregistrements , Examen des urinesRÉSUMÉ
CD163 is a marker for alternatively activated macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). In our preliminary screening of urine proteins in LN, urine soluble CD163 (sCD163) was significantly elevated in patients with active LN. To evaluate the potential of sCD163 as a biomarker in LN, urine sCD163 was assayed in patients with active LN, active non-renal lupus patients (ANR), inactive SLE and healthy controls (HC), using ELISA and normalized to urine creatinine. The correlation of urine sCD163 with clinical parameters and renal pathological attributes was further investigated in LN patients with concurrent renal biopsies. A total of 228 SLE patients and 56 HC were included from three cohorts. Results demonstrated that urine sCD163 was significantly elevated in active LN when compared with HC, inactive SLE, or ANR in African-American, Caucasian and Asian subjects (all P < 0.001). In LN patients with concurrent renal biopsies, urine sCD163 was significantly increased in patients with proliferative LN when compared with non-proliferative LN (P < 0.001). Urine sCD163 strongly correlated with SLEDAI, rSLEDAI, activity index (AI) of renal pathology, fibrinoid necrosis, cellular crescents, and interstitial inflammation on biopsies (all P < 0.01). Macrophages, particularly M2 macrophages, the predominant cells expressing CD163 within LN kidneys, represented a potential source of elevated urine sCD163, based on single-cell RNA sequencing analysis. To conclude, urine sCD163 discriminated patients with active LN from other SLE patients and was significantly elevated in proliferative LN. It strongly correlated with concurrent AI and several specific pathological attributes, demonstrating its potential in predicting renal pathology.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Marqueurs biologiques/urine , Rein/anatomopathologie , Lupus érythémateux disséminé/immunologie , Glomérulonéphrite lupique/immunologie , Macrophages/immunologie , Adulte , Différenciation cellulaire , Prolifération cellulaire , Femelle , Fibrose , Humains , Lupus érythémateux disséminé/diagnostic , Glomérulonéphrite lupique/diagnostic , Mâle , Nécrose , Récepteurs de surface cellulaire , Lymphocytes auxiliaires Th2/immunologieRÉSUMÉ
BACKGROUND: Clinical distinction between patients with lupus nephritis who have active inflammation or chronic kidney damage is challenging. Studies have shown soluble CD163, which derives from cleavage of the CD163 M2c macrophage receptor and can be quantified in urine, correlates with active lupus nephritis. METHODS: We measured urine CD163 at lupus nephritis flares in patients from a Mexican cohort and cross-sectional and longitudinal United States cohorts. We also performed serial urine CD163 measurements during the treatment of flares in a subset of patients from the Mexican and longitudinal United States cohorts, and assessed response to therapy at 12 months. In addition, we evaluated urinary CD163 agreement with histologic activity in 19 patients from the Mexican cohort who had repeated kidney biopsies on follow-up. RESULTS: Urinary CD163 levels were significantly higher in patients with active lupus nephritis than in patients with active extrarenal SLE, inactive SLE, and other glomerular diseases, and correlated with disease clinical severity, histologic class, and the histologic activity index. Urinary CD163 increased from 6 months preflare to flare, diminishing progressively in complete and partial responders, whereas it remained elevated in nonresponders. Urinary CD163 <370 ng/mmol at 6 months predicted complete renal response at 12 months with >87% sensitivity and >87% specificity. Urinary CD163 <370 ng/mmol or >370 ng/mmol perfectly agreed (κ=1.0) with a histologic activity index ≤1 or >1 in repeated biopsies, respectively. Evaluation of urinary CD163 in patients with persistent proteinuria at 6 months improved the prediction of who would achieve complete renal response at 12 months. CONCLUSIONS: Urinary CD163 reflects histologic inflammation in lupus nephritis and is a promising activity biomarker that varies over time with lupus nephritis activity and treatment.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Glomérulonéphrite lupique/urine , Adulte , Marqueurs biologiques/urine , Femelle , Humains , Glomérulonéphrite lupique/diagnostic , Glomérulonéphrite lupique/anatomopathologie , Mâle , Adulte d'âge moyen , Récepteurs de surface cellulaireRÉSUMÉ
BACKGROUND: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1). METHODS: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV. RESULTS: Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8-1.2] in remission and 1.4 mg/dL (IQR 1.0-1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79-337), 44 (17-104) and 38 (7-76), respectively (P < 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6-23.5), 4.1 (2.5-8.4) and 4.1 (1.9-6.8), respectively (P < 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P < 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2. CONCLUSION: A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/complications , Anticorps anti-cytoplasme des polynucléaires neutrophiles/effets indésirables , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Marqueurs biologiques/urine , Chimiokine CCL2/urine , Maladies du rein/diagnostic , Adulte , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/immunologie , Anticorps anti-cytoplasme des polynucléaires neutrophiles/immunologie , Femelle , Humains , Maladies du rein/étiologie , Maladies du rein/urine , Études longitudinales , Mâle , Adulte d'âge moyen , Récepteurs de surface cellulaire , Examen des urinesRÉSUMÉ
Background: Early detection of renal involvement in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is of major clinical importance to allow prompt initiation of treatment and limit renal damage. Urinary soluble cluster of differentiation 163 (usCD163) has recently been identified as a potential biomarker for active renal vasculitis. However, a significant number of patients with active renal vasculitis test negative using usCD163. We therefore studied whether soluble CD25 (sCD25), a T cell activation marker, could improve the detection of renal flares in AAV. Methods: sCD25 and sCD163 levels in serum and urine were measured by enzyme-linked immunosorbent assay in 72 patients with active renal AAV, 20 with active extrarenal disease, 62 patients in remission and 18 healthy controls. Urinary and blood CD4+ T and CD4+ T effector memory (TEM) cell counts were measured in 22 patients with active renal vasculitis. Receiver operating characteristics (ROC) curves were generated and recursive partitioning was used to calculate whether usCD25 and serum soluble CD25 (ssCD25) add utility to usCD163. Results: usCD25, ssCD25 and usCD163 levels were significantly higher during active renal disease and significantly decreased after induction of remission. A combination of usCD25, usCD163 and ssCD25 outperformed all individual markers (sensitivity 84.7%, specificity 95.1%). Patients positive for sCD25 but negative for usCD163 (n = 10) had significantly higher C-reactive protein levels and significantly lower serum creatinine and proteinuria levels compared with the usCD163-positive patients. usCD25 correlated positively with urinary CD4+ T and CD4+ TEM cell numbers, whereas ssCD25 correlated negatively with circulating CD4+ T and CD4+ TEM cells. Conclusion: Measurement of usCD25 and ssCD25 complements usCD163 in the detection of active renal vasculitis.
Sujet(s)
Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/sang , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/urine , Antigènes CD/sang , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/sang , Antigènes de différenciation des myélomonocytes/urine , Sous-unité alpha du récepteur à l'interleukine-2/sang , Maladies du rein/sang , Maladies du rein/urine , Récepteurs de surface cellulaire/sang , Adulte , Sujet âgé , Anticorps anti-cytoplasme des polynucléaires neutrophiles/sang , Anticorps anti-cytoplasme des polynucléaires neutrophiles/urine , Autoanticorps , Marqueurs biologiques/sang , Marqueurs biologiques/urine , Lymphocytes T CD4+/immunologie , Études de cohortes , Test ELISA , Femelle , Humains , Mâle , Adulte d'âge moyen , Courbe ROC , Sensibilité et spécificitéRÉSUMÉ
OBJECTIVE: To evaluate the performance of serum and urinary sCD163 concentrations as possible biomarker in systemic sclerosis (SSc). METHODS: Urine and serum samples were obtained from SSc patients and age- and sex-matched controls. Serum and urinary sCD163 concentrations were measured by commercially available ELISA kit. SSc patients were assessed following international guidelines. Cross-sectional analyses were performed. RESULTS: Two hundred and three SSc patients were included. The control group consisted of 47 age- and sex-matched patients having noninflammatory diseases, mainly osteoporosis. Serum sCD163 levels were significantly higher in SSc patients compared with controls (mean ± SD: 529 ± 251 versus 385 ± 153 ng/mL; p < 0.001). Urinary sCD163 concentrations were higher in SSc patients than controls, but this did not reach significance (236 ± 498 versus 176 ± 173 ng/mg uCr; p = 0.580). The sCD163 concentrations were not associated with clinical, laboratory, and instrumental characteristics of SSc patients. CONCLUSION: To our knowledge, this is the first evaluation of both serum and urinary sCD163 levels in SSc. Our results show a significant difference for sera values that should be prioritized for further studies as compared to urinary measurements. Our results further support that the M2 macrophages/CD163 signaling system may play a role in the pathogenesis of SSc, although we could not identify a subset of SSc patients with higher concentrations.
Sujet(s)
Antigènes CD/sang , Antigènes de différenciation des myélomonocytes/sang , Récepteurs de surface cellulaire/sang , Sclérodermie systémique/sang , Adulte , Sujet âgé , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Marqueurs biologiques/sang , Marqueurs biologiques/urine , Études cas-témoins , Femelle , Humains , Mâle , Adulte d'âge moyen , Sclérodermie systémique/urineRÉSUMÉ
PURPOSE OF REVIEW: Biomarkers are considered to be helpful in diagnosing, monitoring, predicting treatment response, and prognosis in clinical practice and as outcomes in clinical trials. In this article, we review the recent literature on new biomarkers and the expanding use of older ones in vasculitic conditions. RECENT FINDINGS: In antineutrophil cytoplasmic antibody-associated vasculitis patients antineutrophil cytoplasmic antibody type may be useful as a predictor of relapse and response to rituximab. Moreover, serial measurements of proteinase-3 titer may help to predict relapse. Urinary soluble CD163 levels are promising for identifying active renal vasculitis. Imaging modalities such as positron emission tomography, computerized angiography tomography, and temporal artery ultrasound maintain their role in diagnosis and disease assessment in large vessel vasculitis. Fecal calprotectin is a useful marker of active gastrointestinal involvement in Behçet's syndrome. SUMMARY: The publications reviewed here potentially may help to move the field of biomarkers in vasculitis management. However, more work toward understanding the underlying pathophysiology and effects of an intervention on the disease process are needed before true biomarkers can be realized. Further studies with appropriate control groups, using good definitions for disease states such as activity and remission are needed to guide our use of these markers correctly in the management of our patients.
Sujet(s)
Anticorps anti-cytoplasme des polynucléaires neutrophiles/immunologie , Myéloblastine/immunologie , Vascularite/métabolisme , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/sang , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/diagnostic , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/traitement médicamenteux , Vascularites associées aux anticorps anti-cytoplasme des neutrophiles/immunologie , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Antirhumatismaux/usage thérapeutique , Autoanticorps , Maladie de Behçet/métabolisme , Marqueurs biologiques/métabolisme , Angiographie par tomodensitométrie , Fèces/composition chimique , Maladies gastro-intestinales/diagnostic , Maladies gastro-intestinales/métabolisme , Humains , Maladies du rein/diagnostic , Maladies du rein/urine , Complexe antigénique L1 leucocytaire/métabolisme , Maladie de Kawasaki/diagnostic , Maladie de Kawasaki/immunologie , Maladie de Kawasaki/métabolisme , Polyartérite noueuse/diagnostic , Polyartérite noueuse/immunologie , Polyartérite noueuse/métabolisme , Tomographie par émission de positons , Pronostic , Récepteurs de surface cellulaire , Récidive , Rituximab/usage thérapeutique , Artères temporales/imagerie diagnostique , Échographie , Vascularite/diagnostic , Vascularite/immunologieRÉSUMÉ
BACKGROUND: In addition to classically activated macrophages that have effector roles in tissue injury, alternatively activated M2 macrophages are involved in the resolution of inflammation in animal models of kidney disease. To clarify the clinical relevance of macrophage phenotypes in human glomerular diseases, we evaluated the renal accumulation of macrophages and plasma and urine levels of CD163, an M2 marker, in lupus nephritis (LN) patients. METHODS: Kidney biopsies and plasma and urine samples were obtained from LN patients who underwent renal biopsy between 2008 and 2012. CD163+, CD68+ and CD204+ cells were counted in paraffin-embedded and frozen sections. LN histological activity was evaluated semiquantitatively using the biopsy activity index. Plasma and urinary soluble CD163 (sCD163) concentrations were also measured and evaluated for their significance as potential LN biomarkers. RESULTS: Immunohistological analysis of glomeruli from LN patients revealed that >60% of CD68+ macrophages had merged with CD163+ cells. The increased number of glomerular CD163+ macrophages was correlated with LN severity, as determined by the biopsy active index (r = 0.635). Urinary (u-) sCD163 level was strongly correlated with glomerular CD163+ cell counts and histological disease score as well as urinary monocyte chemoattractant protein 1 levels (r = 0.638 and 0.592, respectively). Furthermore, the u-sCD163 level was higher in patients with active LN than in those with other diseases. CONCLUSIONS: Glomerular CD163+ macrophages are the predominant phenotype in the kidneys of lupus patients. These findings indicate that the u-sCD163 level can serve as a biomarker for macrophage-dependent glomerular inflammation in human LN.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Inflammation/diagnostic , Glomérule rénal/immunologie , Glomérulonéphrite lupique/complications , Macrophages/immunologie , Adulte , Sujet âgé , Marqueurs biologiques/urine , Études de cohortes , Femelle , Humains , Inflammation/étiologie , Inflammation/urine , Glomérule rénal/métabolisme , Glomérule rénal/anatomopathologie , Macrophages/métabolisme , Macrophages/anatomopathologie , Mâle , Adulte d'âge moyen , Phénotype , Récepteurs de surface cellulaireRÉSUMÉ
A specific biomarker that can separate active renal vasculitis from other causes of renal dysfunction is lacking, with a kidney biopsy often being required. Soluble CD163 (sCD163), shed by monocytes and macrophages, has been reported as a potential biomarker in diseases associated with excessive macrophage activation. Thus, we hypothesized that urinary sCD163 shed by crescent macrophages correlates with active glomerular inflammation. We detected sCD163 in rat urine early in the disease course of experimental vasculitis. Moreover, microdissected glomeruli from patients with small vessel vasculitis (SVV) had markedly higher levels of CD163 mRNA than did those from patients with lupus nephritis, diabetic nephropathy, or nephrotic syndrome. Both glomeruli and interstitium of patients with SVV strongly expressed CD163 protein. In 479 individuals, including patients with SVV, disease controls, and healthy controls, serum levels of sCD163 did not differ between the groups. However, in an inception cohort, including 177 patients with SVV, patients with active renal vasculitis had markedly higher urinary sCD163 levels than did patients in remission, disease controls, or healthy controls. Analyses in both internal and external validation cohorts confirmed these results. Setting a derived optimum cutoff for urinary sCD163 of 0.3 ng/mmol creatinine for detection of active renal vasculitis resulted in a sensitivity of 83%, specificity of 96%, and a positive likelihood ratio of 20.8. These data indicate that urinary sCD163 level associates very tightly with active renal vasculitis, and assessing this level may be a noninvasive method for diagnosing renal flare in the setting of a known diagnosis of SVV.
Sujet(s)
Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Maladies du rein/urine , Rein/vascularisation , Vascularite/urine , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/urine , Femelle , Humains , Mâle , Adulte d'âge moyen , Récepteurs de surface cellulaire , Jeune adulteRÉSUMÉ
BACKGROUND: Sepsis is a common syndrome in critically ill patients and easily leads to the occurrence of acute kidney injury (AKI), with high mortality rates. This study aimed to investigate the diagnostic value of urine soluble CD163 (sCD163) for identification of sepsis, severity of sepsis, and for secondary AKI, and to assess the patients' prognosis. METHODS: We enrolled 20 cases with systemic inflammatory response syndrome (SIRS), 40 cases with sepsis (further divided into 17 sepsis cases and 23 severe sepsis cases) admitted to the intensive care unit (ICU), and 20 control cases. Results for urine sCD163 were recorded on the day of admission to the ICU, and AKI occurrence was noted. RESULTS: On the day of ICU admission, the sepsis group exhibited higher levels of urine sCD163 (74.8 ng/ml; range: 47.9-148.3 ng/ml) compared with those in the SIRS group (31.9 ng/ml; 16.8-48.0, P < 0.001). The area under the curve (AUC) was 0.83 (95% confidence interval [CI]: 0.72-0.94, P < 0.001) the sensitivity was 0.83, and the specificity was 0.75 (based on a cut-off point of 43.0 ng/ml). Moreover, the severe sepsis group appeared to have a higher level of sCD163 compared with that in the sepsis group (76.2; 47.2-167.5 ng/ml vs. 74.2; 46.2-131.6 ng/ml), but this was not significant. For 15 patients with AKI, urine sCD163 levels at AKI diagnosis were significantly higher than those of the remaining 35 sepsis patients upon ICU admission (121.0; 74.6-299.1 ng/ml vs. 61.8; 42.8-128.3 ng/ml, P = 0.049). The AUC for urine sCD163 was 0.688 (95% CI: 0.51-0.87, P = 0.049). Sepsis patients with a poor prognosis showed a higher urine sCD163 level at ICU admission (98.6; 50.3-275.6 ng/ml vs. 68.0; 44.8-114.5 ng/ml), but this was not significant. Patients with AKI with a poor prognosis had higher sCD163 levels than those in patients with a better prognosis (205.9; 38.6-766.0 ng/ml vs. 80.9; 74.9-141.0 ng/ml), but this was not significant. CONCLUSIONS: This study shows, for the first time, the potential value of urine sCD163 levels for identifying sepsis and diagnosing AKI, as well as for assessment of patients' prognosis. TRIAL REGISTRATION: ChiCTR-ONC-10000812.
Sujet(s)
Atteinte rénale aigüe/urine , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Sepsie/urine , Syndrome de réponse inflammatoire généralisée/urine , Atteinte rénale aigüe/diagnostic , Atteinte rénale aigüe/épidémiologie , Adulte , Sujet âgé , Marqueurs biologiques/urine , Femelle , Humains , Mâle , Adulte d'âge moyen , Études prospectives , Récepteurs de surface cellulaire , Sepsie/diagnostic , Sepsie/épidémiologie , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/épidémiologieRÉSUMÉ
BACKGROUND: Low birth weight is associated with deficits in nephron number in the infant kidney and increased risk of adulthood hypertension and renal dysfunction. Urinary biomarkers may be potential indicators of renal reserve, but little is known about the influence of gestational and postnatal age on the expression of urinary proteins. The aims of this study were to determine the relationships between selected urinary proteins and renal maturation. We hypothesized that urinary protein patterns would change over time during late nephrogenesis and renal maturation. METHODS: Urine samples were collected at birth and over 12 mo from preterm (33-35 wk) and term (38-40 wk) infants. Candidate urinary proteins were identified by antibody array and quantified with enzyme-linked immunosorbent assay. RESULTS: Preterm infants at birth were found to have relatively elevated levels of insulin-like growth factor binding protein-1, -2, and -6, monocyte chemotactic protein-1, CD14, and sialic acid-binding Ig-like lectin 5. These markers gradually decline to levels similar to those of full-term infants by 2-6 mo of life. In contrast, many urinary markers in healthy full-term infants remain stable over the first year of life. CONCLUSION: Gestational and postnatal age must be considered when evaluating the utility of urinary biomarkers.
Sujet(s)
Régulation de l'expression des gènes au cours du développement/génétique , Prématuré/métabolisme , Rein/croissance et développement , Rein/métabolisme , Protéinurie/urine , Protéome/génétique , Facteurs âges , Antigènes CD/urine , Antigènes de différenciation des myélomonocytes/urine , Chimiokine CCL2/urine , Femelle , Âge gestationnel , Humains , Nourrisson , Nouveau-né , Protéine-1 de liaison aux IGF/urine , Protéine-2 de liaison aux IGF/urine , Protéine-6 de liaison aux IGF/urine , Lectines/urine , Mâle , Statistique non paramétriqueRÉSUMÉ
Here we report that soluble CD14 isolated from the urine of nephrotic patients (uCD14) contains a potent cytokine inducing activity. CD14 derived from urine appeared to consist of two major polypeptides of about 54 and 48 kDa. In uCD14 isolated from three different nephrotic patients the cytokine-inducing activity appeared to co-migrate with the 48-kDa polypeptide which upon sequencing had the same N-terminal sequence as native CD14. Treatment of human monocytes and the human astrocytoma cell line U373 with uCD14 resulted in a strong secretion of tumor necrosis factor (TNF) and interleukin-6, respectively. The cytokine-inducing activity of the uCD14 preparations was unaffected by the absence of serum. This is in contrast to the activation of human monocytes and U373 cells by lipopolysaccharide (LPS) which is highly dependent on the presence of serum. The cytokine-inducing activity was not affected by LPS-binding protein (LBP) or polyclonal rabbit antibodies against LBP. The TNF-inducing activity of uCD14 was also heat labile in contrast to the cytokine-inducing activity of LPS, which was relatively heat resistant. The results suggest that CD14 may exist in at least two forms of which one is involved in cytokine induction.